In this video, Jonathan A. Bernstein, MD, discusses findings about chronic itch presented at the American College of Allergy, ...

In this video, Jonathan A. Bernstein, MD, discusses his American College of Allergy, Asthma & Immunology Annual Scientific ...

Large M&A transactions and bidding wars for Metsera and Avadel announced in H2 2025 reflect a need for large pharma companies to replenish pipelines through M&A ahead of looming patent cliffs.

REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models ...

Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST. Read the latest ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

The next few years of projected revenues in the pharma space have more holes in them than industry CEOs’ favorite golf ...

M&A in biopharma is shaped by policy uncertainties, tariffs, and potential marketing rule changes, influencing strategic ...

France’s investment banking market recovered strongly in 2025 but that doesn’t mean domestic banks are happy. The market is ...

New long-term clinical data for Blueprint Medicines' drug Ayvakit (avapritinib) were presented at the ASH congress in Orlando, reinforcing the treatment's pr ...

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...